Research Summary

Dr. Butowski specializes in novel therapeutic approaches to brain tumors, clinical trials, neuro-imaging, cognitive and rehabilitative neurology, medical education, and complementary therapy. His ultimate research goal is to develop novel and effective therapeutic strategies for the treatment of patients with primary brain tumors. The most direct research application is the design and conduct of phase I, II, and III clinical trials, and Dr. Butowski is a co-investigator of National Cancer Institute-supported North American Brain Tumor Consortium clinical trials. As a member of the Brain Tumor Research Center at UCSF, his research goals have expanded to include the evaluation of novel imaging techniques and molecular profiling methods that may influence the selection of patients for treatment. His research interests also include methods and/or treatments to ensure good quality of life for patients with brain tumors and methods and/or treatments that may assist patients in recovering from or coping with brain injury. The majority of his clinical activities involve the assessment and management of adult patients with brain tumors.

Research Funding

  • April 1, 2014 - March 31, 2016 - A Phase I Study of CED of Liposomal-Irinotecan using imaging in High Grade Glioma, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R21CA186140
  • April 1, 2014 - March 31, 2017 - A Phase I Study of CED of Liposomal-Irinotecan using imaging in High Grade Glioma, Principal Investigator. Sponsor: NIH, Sponsor Award ID: R21CA186140

Education

Northwestern University, Evanston, IL, BA, 1991-1995, Philosophy/Religion
University of Illinois at Chicago, Chicago, IL, MD, 1995-1999
Evanston-Northwestern Hospital, Evanston, IL, Surgical Intern, 1999-2000
UCSF Department of Neurology, Resident, 2000-2003
UCSF Department of Neurological Surgery, Neuro-Oncology Fellow, 2003-2004

Selected Publications

  1. Haddad AF, Young JS, Amara D, Berger MS, Raleigh DR, Aghi MK, Butowski NA. Mouse models of glioblastoma for the evaluation of novel therapeutic strategies. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab100.  View on PubMed
  2. Ellingson BM, Patel K, Wang C, Raymond C, Brenner A, de Groot JF, Butowski NA, Zach L, Campian JL, Schlossman J, Rizvi S, Cohen YC, Lowenton-Spier N, Minei TR, Shmueli SF, Wen PY, Cloughesy TF. Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab082.  View on PubMed
  3. Bush NAO, Young JS, Zhang Y, Dalle Ore CL, Molinaro AM, Taylor J, Clarke J, Prados M, Braunstein SE, Raleigh DR, Chang SM, Berger MS, Butowski NA. A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma. J Neurooncol. 2021 Jul; 153(3):447-454.  View on PubMed
  4. Shuford S, Lipinski L, Abad A, Smith AM, Rayner M, O'Donnell L, Stuart J, Mechtler LL, Fabiano AJ, Edenfield J, Kanos C, Gardner S, Hodge P, Lynn M, Butowski NA, Han SJ, Redjal N, Crosswell HE, Vibat CRT, Holmes L, Gevaert M, Fenstermaker RA, DesRochers TM. Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab065.  View on PubMed
  5. Ellingson BM, Sampson J, Achrol AS, Aghi MK, Bankiewicz K, Wang C, Bexon M, Brem S, Brenner A, Chowdhary S, Floyd JR, Han S, Kesari S, Randazzo D, Vogelbaum MA, Vrionis F, Zabek M, Butowski N, Coello M, Merchant N, Merchant F. Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma. Clin Cancer Res. 2021 Jul 15; 27(14):3916-3925.  View on PubMed
  6. Yu Y, Villanueva-Meyer J, Grimmer MR, Hilz S, Solomon DA, Choi S, Wahl M, Mazor T, Hong C, Shai A, Phillips JJ, Wainer BH, McDermott M, Haas-Kogan D, Taylor JW, Butowski N, Clarke JL, Berger MS, Molinaro AM, Chang SM, Costello JF, Oberheim Bush NA. Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. Neuro Oncol. 2021 Apr 05.  View on PubMed
  7. Mrugala MM, Ostrom QT, Pressley SM, Taylor JW, Thomas AA, Wefel JS, Coven SL, Acquaye AA, Haynes C, Agnihotri S, Lim M, Peters KB, Sulman EP, Salcido JT, Butowski NA, Hervey-Jumper S, Mansouri A, Oliver KR, Porter AB, Nassiri F, Schiff D, Dunbar EM, Hegi ME, Armstrong TS, van den Bent MJ, Chang SM, Zadeh G, Chheda MG. The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab035.  View on PubMed
  8. Cloughesy TF, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, Damek D, Bota D, Bettegowda C, Zhu JJ, Iwamoto F, Placantonakis D, Kim L, Elder B, Kaptain G, Cachia D, Moshel Y, Brem S, Piccioni D, Landolfi J, Chen CC, Gruber H, Rao AR, Hogan D, Accomando W, Ostertag D, Montellano TT, Kheoh T, Kabbinavar F, Vogelbaum MA. Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial. JAMA Oncol. 2020 12 01; 6(12):1939-1946.  View on PubMed
  9. Nabors LB, Portnow J, Ahluwalia M, Baehring J, Brem H, Brem S, Butowski N, Campian JL, Clark SW, Fabiano AJ, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Horbinski C, Junck L, Kaley T, Kumthekar P, Loeffler JS, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Robins I, Rockhill J, Rusthoven C, Shonka N, Shrieve DC, Swinnen LJ, Weiss S, Wen PY, Willmarth NE, Bergman MA, Darlow SD. Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 11 02; 18(11):1537-1570.  View on PubMed
  10. Schulte JD, Buerki RA, Lapointe S, Molinaro AM, Zhang Y, Villanueva-Meyer JE, Perry A, Phillips JJ, Tihan T, Bollen AW, Pekmezci M, Butowski N, Oberheim Bush NA, Taylor JW, Chang SM, Theodosopoulos P, Aghi MK, Hervey-Jumper SL, Berger MS, Solomon DA, Clarke JL. Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa142.  View on PubMed
  11. Ramani B, Gupta R, Wu J, Barreto J, Bollen AW, Tihan T, Mummaneni PV, Ames C, Clark A, Oberheim Bush NA, Butowski N, Phillips D, King BE, Bator SM, Treynor EC, Zherebitskiy V, Quinn PS, Walker JB, Pekmezci M, Sullivan DV, Hofmann JW, Sloan EA, M Chang S, Berger MS, Solomon DA, Perry A. The immunohistochemical, DNA methylation, and chromosomal copy number profile of cauda equina paraganglioma is distinct from extra-spinal paraganglioma. Acta Neuropathol. 2020 12; 140(6):907-917.  View on PubMed
  12. Lucas CG, Gupta R, Doo P, Lee JC, Cadwell CR, Ramani B, Hofmann JW, Sloan EA, Kleinschmidt-DeMasters BK, Lee HS, Wood MD, Grafe M, Born D, Vogel H, Salamat S, Puccetti D, Scharnhorst D, Samuel D, Cooney T, Cham E, Jin LW, Khatib Z, Maher O, Chamyan G, Brathwaite C, Bannykh S, Mueller S, Kline CN, Banerjee A, Reddy A, Taylor JW, Clarke JL, Oberheim Bush NA, Butowski N, Gupta N, Auguste KI, Sun PP, Roland JL, Raffel C, Aghi MK, Theodosopoulos P, Chang E, Hervey-Jumper S, Phillips JJ, Pekmezci M, Bollen AW, Tihan T, Chang S, Berger MS, Perry A, Solomon DA. Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor. Acta Neuropathol Commun. 2020 08 28; 8(1):151.  View on PubMed
  13. Cloughesy TF, Brenner A, de Groot JF, Butowski NA, Zach L, Campian JL, Ellingson BM, Freedman LS, Cohen YC, Lowenton-Spier N, Rachmilewitz Minei T, Fain Shmueli S, GLOBE Study Investigators , Wen PY. A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). Neuro Oncol. 2020 05 15; 22(5):705-717.  View on PubMed
  14. Morshed RA, Reihl SJ, Molinaro AM, Kakaizada S, Young JS, Schulte JD, Butowski N, Taylor J, Bush NA, Aghi MK, Berger MS, Chang S, Clarke J, Hervey-Jumper SL. The influence of race and socioeconomic status on therapeutic clinical trial screening and enrollment. J Neurooncol. 2020 May; 148(1):131-139.  View on PubMed
  15. Rodriguez-Almaraz JE, Chang S, Clarke J, Oberheim-Bush NA, Taylor J, Buerki R, Berger M, Zablotska L, Lobach I, Butowski N. A systematic review and meta-analysis examining the effects of cannabis and its derivatives in adults with malignant CNS tumors. Neurooncol Pract. 2020 Jul; 7(4):376-383.  View on PubMed
  16. Molinaro AM, Hervey-Jumper S, Morshed RA, Young J, Han SJ, Chunduru P, Zhang Y, Phillips JJ, Shai A, Lafontaine M, Crane J, Chandra A, Flanigan P, Jahangiri A, Cioffi G, Ostrom Q, Anderson JE, Badve C, Barnholtz-Sloan J, Sloan AE, Erickson BJ, Decker PA, Kosel ML, LaChance D, Eckel-Passow J, Jenkins R, Villanueva-Meyer J, Rice T, Wrensch M, Wiencke JK, Oberheim Bush NA, Taylor J, Butowski N, Prados M, Clarke J, Chang S, Chang E, Aghi M, Theodosopoulos P, McDermott M, Berger MS. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. JAMA Oncol. 2020 04 01; 6(4):495-503.  View on PubMed
  17. Sloan EA, Cooney T, Oberheim Bush NA, Buerki R, Taylor J, Clarke JL, Torkildson J, Kline C, Reddy A, Mueller S, Banerjee A, Butowski N, Chang S, Mummaneni PV, Chou D, Tan L, Theodosopoulos P, McDermott M, Berger M, Raffel C, Gupta N, Sun PP, Li Y, Shah V, Cha S, Braunstein S, Raleigh DR, Samuel D, Scharnhorst D, Fata C, Guo H, Moes G, Kim JYH, Koschmann C, Van Ziffle J, Onodera C, Devine P, Grenert JP, Lee JC, Pekmezci M, Phillips JJ, Tihan T, Bollen AW, Perry A, Solomon DA. Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas. Acta Neuropathol. 2019 11; 138(5):877-881.  View on PubMed
  18. Butowski NA, Bringas JR, Bankiewicz KS, Aghi MK. Editorial. Chronic convection-enhanced delivery: the next frontier in regional drug infusion for glioblastoma. J Neurosurg. 2019 Aug 02; 1-3.  View on PubMed
  19. Chapman CH, Hara JH, Molinaro AM, Clarke JL, Oberheim Bush NA, Taylor JW, Butowski NA, Chang SM, Fogh SE, Sneed PK, Nakamura JL, Raleigh DR, Braunstein SE. Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survival. Neurooncol Pract. 2019 Sep; 6(5):364-374.  View on PubMed
  20. Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O'Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019 03; 25(3):477-486.  View on PubMed

Go to UCSF Profiles, powered by CTSI